Paolo Tarantino, Advanced Research Fellow at Dana-Farber Cancer Institute and Harvard Medical School, reshared a post by Dana-Farber’s Breast Oncology Center, on X:
“Dr. Isaacs made it clear in her DB09 discussion: we need biomarkers to tailor treatment with T-DXd!
At Dana-Farber’s Breast Oncology Center, we’re committed to develop them.
With the help of terrific partners, we tested HER2DX & RPPA in a pilot of 40 pts.
Intriguing results, working on validation.”
Quoting Dana-Farber’s Breast Oncology Center‘s post:
“Metastatic Breast Cancer Poster Session:
Quantitative pre-treatment assessment of trastuzumab deruxtecan (TDXd) antibody target (HER2) and payload target (topoisomerase 1, Topo1) to predict outcomes in Metastatic Breast Cancer (MBC).
Abstract 1032 | Poster Bd 11 | Jun 2, 9-12 PM CDT | Hall A.”
More posts featuring Paolo Tarantino.